source
- Sevabertinib-related diarrhea in HER2-mutated NSCLC is generally low-grade and manageable, study showsThe SOHO-01 trial examined the safety of sevabertinib in patients with HER2-mutated non-small cell lung cancer, focusing on treatment-related diarrhea. Diarrhea occurred frequently but was mostly…
- Experts discuss managing edema, fatigue and long-term tolerability of antibody-drug conjugates in breast and lung cancerThe piece concludes a series on antibody-drug conjugates, noting that cumulative toxicities can restrict long-term treatment. Dr. Hope Rugo and Dr. Aaron Lisberg point out that edema and fatigue a…